1. Home
  2. KF vs MXCT Comparison

KF vs MXCT Comparison

Compare KF & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Korea Fund Inc. (The) New

KF

Korea Fund Inc. (The) New

HOLD

Current Price

$44.51

Market Cap

151.3M

Sector

Finance

ML Signal

HOLD

Logo MaxCyte Inc.

MXCT

MaxCyte Inc.

HOLD

Current Price

$1.17

Market Cap

160.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KF
MXCT
Founded
1984
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
151.3M
160.0M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
KF
MXCT
Price
$44.51
$1.17
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
$7.50
AVG Volume (30 Days)
18.4K
575.1K
Earning Date
01-01-0001
03-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$34,419,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$11.16
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$18.30
$1.14
52 Week High
$25.56
$5.12

Technical Indicators

Market Signals
Indicator
KF
MXCT
Relative Strength Index (RSI) 79.84 26.45
Support Level $40.83 $1.19
Resistance Level $41.96 $1.28
Average True Range (ATR) 0.79 0.07
MACD 0.34 -0.02
Stochastic Oscillator 90.71 8.79

Price Performance

Historical Comparison
KF
MXCT

About KF Korea Fund Inc. (The) New

Korea Fund Inc is a closed-end, non-diversified management investment company. Its investment objective is to seek long-term capital appreciation through investment in securities, equity securities, of Korean companies. Its portfolio consists of the different sectors such as the auto components, banks, beverages, chemicals, aerospace and defense, insurance, machinery, and Others.

About MXCT MaxCyte Inc.

MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.

Share on Social Networks: